Impulse control disorders and subthalamic nucleus stimulation in Parkinson's disease: are we jumping the gun?
Moro
E
E
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D046690:Deep Brain Stimulation / Q000009:adverse effects*; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000209:etiology* / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D012737:Sex Factors; D020531:Subthalamic Nucleus / Q000503:physiopathology*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D004298:Dopamine